Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Completed 8Unknown 7Recruiting 3Withdrawn 1Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Endocrine 1

Conditions

Colonic Neoplasms 2Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 198Cisplatin 188Magnetic Resonance Spectroscopy 168Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 118Paclitaxel 112Oxaliplatin 110Biopsy 107venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 70sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × FOLFOXIRI protocol × Clear all
NCT04325425 2025-09-30

FOLFIRINEC

Centre Hospitalier Universitaire Dijon

Phase 2 Recruiting
218 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT06242418 2024-12-12

REVISE

West China Hospital

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Colonic Neoplasms

NCT06575127 2024-08-28

Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study

Al-Azhar University

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Colonic Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡